Taysha Gene Therapies, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; filed November 14, 2023. Financial statements are unaudited. Taysha is a clinical-stage gene-therapy company with no approved products and no product-sales revenue.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $4.7m | $0 | $11.8m | $0 |
| Research and development | $11.8m | $16.8m | $44.1m | $78.5m |
| General and administrative | $8.6m | $8.7m | $23.3m | $30.0m |
| Operating loss | $16.3m | $25.5m | $56.2m | $108.5m |
| Net loss | $117.1m | $26.5m | $159.3m | $110.9m |
| Operating cash used | — | — | $56.9m | $103.1m |
Revenue came from the Astellas agreement: Rett research and development activities and recognition of the GAN option-related amount after Astellas declined to exercise that option. The company has not generated product-sales revenue. Gross margin is not meaningful for its current development-stage operations.
At September 30, cash and cash equivalents were $164.3m, with an additional $2.6m of restricted cash. Management said existing cash was expected to fund planned operations into 2026 and for at least 12 months after issuance of the statements; it also said additional capital will be required. Nine-month investing cash outflow was $7.3m and financing cash inflow was $140.6m, principally reflecting the August private placement.
Total assets were $195.8m and total liabilities were $244.9m, resulting in a $49.1m stockholders’ deficit. Current liabilities included a $140.5m warrant liability; the company reported $38.5m of term debt, net, at period-end. The warrant liability’s $100.5m fair-value increase was a noncash expense, substantially driving the reported net loss. The filing reports no income-tax provision, reflecting operating losses and a full valuation allowance against deferred tax assets.
Material changes and notable transactions
- R&D expense fell $34.4m for the first nine months versus 2022, mainly due to reprioritization, lower headcount, fewer manufacturing and raw-material purchases, and reduced external preclinical work; increased Rett trial activity partly offset the decline. G&A fell $6.7m.
- In August, Taysha completed a private placement of common shares and pre-funded warrants for approximately $150m gross and $140.3m net. It issued 122.4m common shares and warrants for 44.3m additional shares. Common shares outstanding rose to 187.0m at September 30 from 63.2m at year-end 2022.
- The pre-funded warrants were classified as liabilities because authorized shares were insufficient for exercise. Their exercise required stockholder approval to increase authorized common shares from 200m to 400m. Failure to obtain approval by December 31, 2023 could trigger liquidated damages of 2% of the relevant purchase price, with additional 2% payments for subsequent missed approval deadlines.
- On November 13, after quarter-end, Taysha borrowed $40m under a Trinity term loan and used the proceeds to repay and terminate its Silicon Valley Bank loan. Trinity debt bears interest at the greater of prime plus 4.50% or 12.75%, is secured by company assets, and has a 5% end-of-term payment. It is interest-only for 36 months, potentially extendable to 48 months, with maturity in November 2028.
- Q3 included a $0.6m noncash impairment when equipment intended for the Durham manufacturing facility was classified as held for sale. Taysha had previously stopped building out that facility.
Programs, outlook and risks
- Rett syndrome / TSHA-102: The Phase 1/2 REVEAL trial had dosed two adult patients by the filing date. The company reported no treatment-emergent serious adverse events at the stated follow-up points and described preliminary clinical observations; these are early, uncontrolled observations and may not predict trial outcomes. The IDMC cleared dosing of a third patient in November, after quarter-end. Taysha expected further low-dose-cohort data in Q1 2024 and planned to dose the first pediatric patient in Q1 2024. FDA had cleared the pediatric IND in August; TSHA-102 has FDA Fast Track designation.
- GAN / TSHA-120: In September, following FDA Type C meeting feedback on a registrational path, Taysha announced it would discontinue development and seek external strategic options. Astellas separately elected not to exercise its GAN option. Taysha disclosed a July notice from Hannah’s Hope Foundation alleging breach of the TSHA-120 license; Taysha disputes the allegation, and resolution is uncertain.
- Taysha expects significant ongoing losses and R&D spending, particularly for Rett, and says future capital needs depend on trial progress, regulatory outcomes, manufacturing and other factors. Clinical development is uncertain; financing may not be available on acceptable terms. The company had previously identified substantial doubt about going concern, but said the August financing resolved that doubt and that it had sufficient liquidity for at least 12 months after issuance.
- Other risks include dependence on third-party intellectual-property licenses, possible changes in preliminary clinical data, secured-debt covenants and default remedies, and dilution from outstanding and potential shares. The filing reports no material legal proceedings; management stated disclosure controls were effective as of September 30.
Most important facts for investors to verify
- Current cash runway and actual cash burn against management’s stated expectation of funding planned operations into 2026.
- Stockholder approval of the authorized-share increase, warrant exercise mechanics, and any liquidated damages or resulting dilution.
- Updated, adequately followed clinical safety and efficacy data for TSHA-102, including whether early observations persist and meet trial endpoints.
- Progress on pediatric Rett dosing and the timing and content of subsequent clinical updates.
- Resolution of the Hannah’s Hope Foundation license dispute and whether any partner advances the discontinued TSHA-120 program.
- The full cost and terms of the Trinity refinancing, including variable interest, fees, collateral, and repayment obligations.